WINNING THE BATTLE AGAINST ENDOTOXIC SEPTIC SHOCK
The first theranostic: EAA™ & Toraymyxin™
Sepsis Alliance Institute Sponsor Innovation Webinar:
Endotoxin, The Phantom Menace of Sepsis
Debra Foster, BSc
Mark A. Tidswell, MD, Professor of Medicine
UMASS Chan Medical School – Baystate
What part does endotoxin play in the etiology of sepsis and septic shock? This sponsored webinar will describe the human response to elevated levels of endotoxin, both as an adaptive immune response and also as a trigger of sepsis. The ability to measure endotoxin activity in the bloodstream allows clinicians to uncloak its true prevalence and closely examine when endotoxin plays a role in sepsis. Can targeting endotoxin removal be a successful treatment modality for sepsis? Tune in to this webinar to learn more.
Thursday October 3, 2024 @ 11am PT | 2pm ET
Replay coming soon.
Sepsis Awareness
Sepsis is a life-threatening condition triggered by the body’s overwhelming response to bacterial components such as endotoxin and it continues to be a major global health issue, impacting millions. If not recognized and treated promptly, sepsis can result in multiple organ failure, shock, and even death.
September marked Sepsis Awareness Month, with numerous events held globally to raise awareness and support this important cause.
At Spectral Medical Inc, we remain dedicated to fighting endotoxic septic shock with our unique theranostic approach. This approach combines the EAA™ Endotoxin Activity Assay for rapid diagnosis, followed by targeted endotoxin removal with Toraymyxin™ PMX extracorporeal hemoperfusion.
This past September, our Sepsis awareness efforts began with the month-long ‘Step-Up’ walking challenge. For World Sepsis Day, we hosted a lunch-and-learn for employees, focusing on the severe effects of sepsis and educating our team on how to recognize the symptoms early. We concluded our campaign with a 3K Walkathon, bringing our employees together to support this important cause.
PRESS RELEASE
Spectral Medical Provides September Tigris Trial Update
132 patients enrolled TORONTO, Canada – October 3, 2024 - Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the...
Spectral Medical Provides August Tigris Trial Update
Management provides view on recently announced Vantive-Carlyle Group transaction TORONTO, Canada – September 3, 2024 - Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for...
Spectral Medical Announces Second Quarter Results and Provides Corporate Update
Tigris Trial Enrollment Reaches 126 Patients
Strengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment
August 9, 2024
Spectral Medical Provides July Tigris Trial Update
125 patients enrolled Record July patient enrollment to start the second half of 2024 TORONTO, Canada – August 1, 2024 - Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for...
investor updates
Investor Update September 2024
crrt conference 2024 REPLAY
CRRT Conference Breakfast Symposium
Waking up to Endotoxemic Septic Shock. What do you need to be ready?
Wednesday March 13, 2024
San Diego, CA
Moderators: John Kellum and Debra Foster
Diagnosing ESS in the real world – Danielle Davison, George Washington University
Treating ESS in the real world – Javier Neyra, University of Alabama
Implementing PMX hemoadsorption at the bedside – Johann Chang, (Spectral), Tara Morgan-Gray, (Colorado Springs)
the balancing act on lifetime tv
Endotoxic Septic Shock as featured on The Balancing Act on Lifetime TV.